Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“My Weekly Take | Breast Cancer
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
New England Journal of Medicine
ADC–immunotherapy combinations are emerging as a new first-line standard in PD-L1–positive metastatic TNBC.
Neoadjuvant Taxane plus Trastuzumab and Pertuzumab With or Without Carboplatin (neoCARHP Trial)
Journal of Clinical Oncology
Carboplatin omission is feasible in HER2-positive neoadjuvant therapy without compromising pCR.
Rise and Fall of Neoadjuvant Carboplatin for HER2-Positive Breast Cancer
Journal of Clinical Oncology
pCR gains with carboplatin have not consistently translated into long-term benefit, supporting selective de-escalation.
HER2CLIMB-05: Tucatinib vs Placebo With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy in HER2-Positive Metastatic Breast Cancer
Journal of Clinical Oncology
Tucatinib-based maintenance significantly prolongs PFS, particularly relevant for higher-risk patients.
Bridging the Gap: Advancing First-Line Therapy for Metastatic HER2-Positive Breast Cancer
Journal of Clinical Oncology
First-line HER2-positive metastatic treatment is shifting toward earlier biologically driven intensification.
Pembrolizumab and Paclitaxel in HR+/HER2− Breast Cancer With HER2-Enriched or Basal-Like Subtypes
Clinical Cancer Research
Intrinsic subtype outperforms PD-L1 in identifying immunotherapy-sensitive HR+ breast cancers.
Exploring the Treatment Gap and Outcome Risks in Node-Positive, High-Risk HR+/HER2− Early Breast Cancer
ESMO Open
High-risk HR+/HER2− disease remains undertreated in real-world practice, with clear prognostic impact.
Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer
JCO Precision Oncology
Germline BRCA mutations define a higher-risk subgroup even within luminal disease.
Pathological Complete Response With Neoadjuvant Pembrolizumab and Chemotherapy in Non-Metastatic Triple-Negative Inflammatory Breast Cancer ESMO Open
Chemo-immunotherapy improves pCR in TN-IBC, but outcomes remain inferior to non-inflammatory TNBC.”
More posts featuring Benjamin Walbaum